Strategies to Improve Vaccines for the Neonate - Novel vaccine formulations can provide more effective immune protection to newborns. - BioPharm International


Strategies to Improve Vaccines for the Neonate
Novel vaccine formulations can provide more effective immune protection to newborns.

BioPharm International

7. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis. 2003(3):413–418.

8. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006(5):471–484.

9. Wilson HL, Dar A, Napper SK, Lopez MA, Babiuk LA, Mutwiri GK. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int Rev Immunol. 2006(25):183–213.

10. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol. 2006(25):135–54.

11. Higgins D, Marshall JD, Traquina P, Van Nest G, Livingston BD. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines. 2007 (6):747–59.

12. Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 2001(3):655–677.

13. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol. 2006: 177, 7980–7989.

14. Gold MC, Donnelly E, Cook MS, Leclair CM, Lewinsohn DA. Purified neonatal plasmacytoid dendritic cells overcome intrinsic maturation defect with TLR agonist stimulation. Pediatr Res. 2006(60):34–37.

15. Sun CM, Deriaud E, Leclerc C, Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL-12 dependent Th-1 priming capacity of neonatal dendritic cells. Immunity. 2006(22):467–477.

16. Tasker, Marshall-Clarke S. Functional responses of human neonatal B lymphocytes to antigen receptor cross-linking and CpG DNA. Clin Exp Immunol. 2003(134):409–419.

17. Landers, CD, Bondada, S. CpG oligodeoxynucleotides stimulate cord blood mononuclear cells to produce immunoglobulins. Clin Immunol. 2005(116):236–245.

18. De Wit D, Olislagers V, Goriely S, Vermeulen F, Wagner H, Goldman M, Willems F. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood. 2004;103, 1030–1032.

19. Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy. 2005(35):1557–1564.

20. Oppenheim JJ, Biragun A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis. 2003(62):17–21.

21. Bowdish DM, Davidson DJ, and Hancock, R.E. Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol. Immunol. 2006;306:27–66.

22. Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol. 2006(18):24–30.

23. Mookherjee N, et al. Modulation of the TLT-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol. 2006(176):2455–2464.

24. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim, JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004;22:(181–215).

25. Yang D, et al. Beta-defensins: Linking innate and adaptive immunity through dendritic and T-cell CCR6. Science. 1999(286):525–528.

26. Yang D, Chertov O, Oppenheim, JJ. Participation of mammalian defensins and cathelicidins in antimicrobial immunity: Receptors and activities of human defensins and cathelicidin (LL-37). J Leuko Biol. 2001(69):691–697.

blog comments powered by Disqus



NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here